ArticleJournal of neurochemistry2025
Multiple Antibody-Coated Gold Nanoparticle-Based ExoAssay for Rapid Isolation of CNS-Specific Exosomes From Blood.
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Markers and Enrichment Strategies for Brain-Derived Extracellular Vesicles: Current Evidence, Limitations and Future Directions.Neuromolecular medicine · 2026Review
- Advancements in Nanomaterial-Based Biosensors for Neuropsychiatric and Neurodegenerative Diagnostics: From Biomarker Discovery to Clinical Translation.Biosensors · 2026Review
- Multiple Antibody-Coated Gold Nanoparticle-Based ExoAssay for Rapid Isolation of CNS-Specific Exosomes From Blood.Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In neurodegenerative diseases, brain-derived extracellular vesicles (EVs)/exosomes from blood offer a great opportunity to explore their contents for their utility as biomarkers. However, the conventional methodologies for the purification of EVs from complex biofluids have many limitations, restricting their clinical implementation. We aimed to optimize a direct, less time-consuming, affordable, and reliable nanowire-based method to isolate neuronal EVs from blood plasma. Here, we improved a simple and direct methodology using multiple antibody-coated magnetic nanowires for efficient and rapid isolation of neuronal EVs (ExoAssay) from human plasma. We characterized the isolated EVs and validated the protocol using multiple approaches, for example, nanoparticle tracking analysis (NTA), immunoblotting, and transmission electron microscopy (TEM). We purified round-shaped EVs with an average size of 116 nm. We identified the general markers of EVs including CD9, CD63, CD81, and Flotillin-1 and two neuronal EV markers L1-cell adhesion molecule (L1CAM) and neural cell adhesion molecule (NCAM) via immunoblotting. Interestingly, the levels of T-Tau and P-Tau were upregulated in EVs isolated from Alzheimer's patients (n = 30), in comparison with healthy controls. Furthermore, there were no significant differences between CSF- and EV-based Tau levels. The high-throughput mass-spectrometry analysis of isolated EVs revealed 280 proteins as significantly modified in Alzheimer's disease cases in comparison with controls. The presented nanotechnology-based methodology offers an innovative and efficient tool for EV-based biomarker investigations and clinical utility by simplifying the enrichment of CNS-originated exosomes from complex biological fluids. This methodology opens up the avenue for longitudinal monitoring of important disease-related proteins in the brain by analysis of brain-derived EVs from blood plasma using simple blood withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.